Drug Trial Radar · NCT04077723
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
498
Planned (sponsor's estimate)
Start
Aug 13, 2019
Primary completion
Dec 28, 2026
Study completion Dec 28, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).
Conditions
- Lymphoma, Non-Hodgkin
Interventions
Englumafusp alfaDrug
Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
ObinutuzumabDrug
A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I). A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III).
GlofitamabDrug
A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III
TocilizumabDrug
Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nature and frequency of dose-limiting toxicities (DLTs)Time frame: 28 days in Part I and Part II
- Proportion of Participants with Adverse Event (AE)Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
- Overall Response Rate (ORR)Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
- Disease Control Rate (DCR)Time frame: Part I: Up to 24 months; Part II: Up to 18 months; Part III: Up to 9 months or up to 18 months
- Duration of Response (DOR)Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination
- Progression-free Survival (PFS)Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination
- Overall Survival (OS)Time frame: After end of Study approximately every 3 months until death, loss to follow-up or study termination
- Complete Response (CR)Time frame: Part III: Up to 9 months or up to 18 months
Locations
35 sites in 12 countries. Site status is shown where the registry gives one.
City of Hope Medical Center
Pasadena, California
University of California San Francisco
San Francisco, California
Washington University School of Medicine
St Louis, Missouri
The University of Texas MD Anderson Cancer Center
Houston, Texas
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
UZ Gent
Ghent, Belgium
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Beijing Cancer Hospital
Beijing, China
Shandong Cancer Hospital
Jinan, China
Fudan University Shanghai Cancer Center
Shanghai, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Aarhus Universitetshospital Skejby
Aarhus N, Denmark
Rigshospitalet
København Ø, Denmark
Odense Universitetshospital
Odense C, Denmark
CHRU de Lille
Lille, France
CHU Montpellier - Saint ELOI
Montpellier, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
CHU DE RENNES - CHU Pontchaillou
Rennes, France
Istituto Nazionale Tumori Irccs Fondazione g. Pascale
Naples, Campania, Italy
Asst Papa Giovanni Xxiii
Bergamo, Lombardy, Italy
Irccs Istituto Europeo Di Oncologia (IEO)
Milan, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
Auckland City Hospital, Cancer and Blood Research
Auckland, New Zealand
Waikato Hospital - Cancer and Blood Research Trials Unit
Hamilton, New Zealand
Pusan National University Hospital
Busan, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Univ. 12 de Octubre
Madrid, Spain
Hospital Clinico Universitario Virgen de la Victoria
Málaga, Spain
The HOPE Clinical Trials Unit
Leicester, United Kingdom
University College London Hospitals NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.